- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02286882
A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects
16. juli 2015 opdateret af: Pfizer
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06409577 In Healthy Adult Subjects
PF-06409577 is a new compound proposed for the treatment of diabetic nephropathy.
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-06409577 in healthy adult subjects.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
39
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Brussels, Belgien, B-1070
- Pfizer Clinical Research Unit
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Healthy male, or female subjects of non childbearing potential.
- Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight >50 kg
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Cohort 1: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 2: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 3: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 4: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 5: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 6: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 7: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 8: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Eksperimentel: Cohort 9: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
|
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of Participants With Adverse Events (AEs)
Tidsramme: 0-48 hours post dose
|
0-48 hours post dose
|
Number of Participants With Laboratory Test Values of Potential Clinical Importance
Tidsramme: 0-48 hours post dose
|
0-48 hours post dose
|
Number of Participants With Vital Signs Findings (Including Bood Pressure and Pulse Rate) of Potential Clinical Importance
Tidsramme: 0-48 hours post dose
|
0-48 hours post dose
|
Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance
Tidsramme: 0-48 hours post dose
|
0-48 hours post dose
|
Number of Participants With Echocardiogram Findings of Potential Clinical Importance
Tidsramme: 0-48 hours post dose
|
0-48 hours post dose
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Curve From Time Zero to Time 24 hours (AUC24) for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post dose
|
Area under the plasma concentration time-curve from zero to time 24 hours post dose (AUC24)
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post dose
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - infinity)] for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
AUC (0 - infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity).
It is obtained from AUC (0 - t) plus AUC (t - infinity).
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Maximum Observed Plasma Concentration (Cmax) for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Maximum Observed Plasma Concentration (Cmax)
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Plasma Decay Half-Life (t1/2) for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Plasma Decay Half-Life (t1/2)
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Apparent Oral Clearance (CL/F) for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Apparent Volume of Distribution (Vz/F) for PF-06409577
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
|
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose
|
Total amount of PF-06409577 excreted in the urine over 24 hours (Ae24)
Tidsramme: 0-24 hours post dose
|
Total amount of unchanged drug excreted in the urine over 24 hours.
|
0-24 hours post dose
|
Total amount of PF-06409577 excreted in the urine over 24 hours, expressed as percent of dose (%Ae24)
Tidsramme: 0-24 hours post dose
|
Total amount of unchanged drug excreted in the urine over 24 hours, expressed as percent of dose.
|
0-24 hours post dose
|
Renal clearance for PF-06409577
Tidsramme: 0-24 hours post dose
|
Renal clearance of a drug is a measure of the rate at which a drug is excreted unchanged into urine.
|
0-24 hours post dose
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. november 2014
Primær færdiggørelse (Faktiske)
1. juni 2015
Studieafslutning (Faktiske)
1. juni 2015
Datoer for studieregistrering
Først indsendt
6. november 2014
Først indsendt, der opfyldte QC-kriterier
6. november 2014
Først opslået (Skøn)
10. november 2014
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
20. juli 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
16. juli 2015
Sidst verificeret
1. juli 2015
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- B7881001
- FIH (Anden identifikator: Alias Study Number)
- 2014-004022-18 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med PF-06409577 or Placebo
-
Devintec SaglMeditrial SrLRekrutteringTilbagevendende aphthous ulcusItalien
-
Ornovi, Inc.Trukket tilbage
-
PfizerRekrutteringAtopisk dermatitisForenede Stater, Canada
-
PfizerTrukket tilbageLuftvejssygdomme | Bronchiale sygdomme | Lungesygdomme, obstruktiv | Astma, bronkial
-
PfizerAfsluttetIkke-alkoholisk fedtleversygdom | Ikke-alkoholisk Steatohepatitis med leverfibroseHong Kong, Forenede Stater, Taiwan, Puerto Rico, Kina, Canada, Korea, Republikken, Bulgarien, Japan, Indien, Polen, Slovakiet
-
PfizerRekrutteringPulmonal arteriel hypertensionForenede Stater
-
PfizerAfsluttetSund og rask | Kronisk rhinosinusitis med næsepolypper | Atopisk dermatitisForenede Stater
-
PfizerAfsluttetPsoriasisCanada, Forenede Stater, Japan, Polen
-
PfizerAfsluttetAnoreksi | Brystkræft | Træthed | Kolorektal cancer | Kræft i bugspytkirtlen | Livmoderhalskræft | Prostatakræft | Kakeksi | Ikke-småcellet lungekræft | Mistet appetitenForenede Stater, Canada
-
PfizerAfsluttet